• About us
  • Core Technology
  • Bio-Service
  • Investors
  • Careers
中文 English
  • About us
    • Introduction
    • Information
      • Announcement
      • Events
      • Corporate image
    • Management Team
      • Members
      • Consultants
    • Contact us
  • Core Technology
    • New medicine development platform
      • Skin diseases
        • ENERGI-F703 ENERGI-F701 ENERGI-F711
      • metabolic diseases
        • ENERGI-F702
      • Anti-inflammation
        • ENERGI-F704 ENERGI-F708
      • Diseases related to deficient mitochondrion
        • ENERGI-F705 ENERGI-F707
      • Others
        • ENERGI-F706 ENERGI-F709 ENERGI-F710
  • Bio-Service
    • Scientific products
      • Western Blot
      • Cell Culture Supplement
      • Protein Isolation
      • Protein Quantification
      • Dyes and Buffer
    • Supplier
      • Lumiprobe
      • Rigaku Reagents
    • Service
      • Quantitative MS and systematic biological analysis experiment service
      • Protein identity certification experiment service
      • Microarray and biological information analysis experiment service
  • Investors
    • Company
    • Financial information
      • Monthly revenue information
      • Financial report
    • Shareholders
      • Shareholders' Meeting
      • Dividend policy and dividend distribution
      • Public specification
      • Stock price information
      • Corporate briefing
      • Important information
      • Investment service window
      • Links
    • Corporate Governance
      • Member of the board
      • Functional committee
      • Various management measures
      • Internal audit
      • Head of Corporate Governance
    • Corporate social responsibility
      • Performance of corporate responsibility
      • Corporate Integrity Zone
      • Stakeholder
  • Careers

About us

  • >
  • About us
  • >
  • Information
  • >
  • Announcement
  • Introduction
  • Information
    • Announcement
    • Events
    • Corporate image
  • Management Team
    • Members
    • Consultants
  • Contact us
2019-12-17
The Israeli patent “Compounds for activating AMPK and the uses thereof.” is granted

Energenesis Biomedical announced that the Israel Patent Office has granted the No. 244752 patent to its invention, which is filed on the 24th of March, 2015. and titled "Compounds for activating AMPK and the uses thereof."

Back
  • +886-2-26270835
  • +886-2-26270836
  • 6F.-3, No.21, Ln.583, Ruiguang Rd., Neihu Dist., Taipei 11492, Taiwan (R.O.C.)
Copyright © 20204 ENERGENESIS BIOMEDICAL CO., LTD. All Rights Reserved. Design by choice